Why Alopecia Areata Is Different from Pattern Baldness

In pattern baldness (androgenetic alopecia), follicles shrink because of a hormone called DHT. But the follicles stay in place. They can be moved, and they keep producing hair. The donor area — the zone at the back and sides of the head where grafts are taken from — is resistant to DHT. So it provides stable grafts. A graft is a small piece of tissue containing one or more hair follicles.

Alopecia areata works differently. The immune system attacks the follicles wherever they are. There is no truly 'stable' donor area. If the condition is active, newly transplanted follicles may be attacked just as your own follicles were.

Hair Often Regrows on Its Own

This point is important, and it is often skipped. In alopecia areata, patches frequently regrow by themselves. Sometimes this takes months, sometimes years. The condition is unpredictable in both directions. Relapse and recovery are both common.

This is exactly why the 1–2 year stability rule exists. Operating too early has two risks. You might transplant into an area that would have recovered on its own — spending donor grafts you can never get back. And the skin may relapse anyway.

When a Transplant May Be Considered

The clinical consensus is that a hair transplant may be considered when all of these are true: the condition has been stable for at least 1–2 years; the patches are permanently bald, not areas likely to regrow; the donor follicles show no signs of shrinking; and you have realistic expectations about the risk of the condition returning.

New Medical Options That May Remove the Need for Surgery

The FDA has approved three medicines called JAK inhibitors for severe alopecia areata: baricitinib (Olumiant) in 2022, ritlecitinib (Litfulo) in 2023, and deuruxolitinib (Leqselvi) in 2024. These were the first targeted treatments for this condition. They work by interrupting the immune signal that attacks hair follicles. In clinical trials, a significant share of patients saw meaningful regrowth. Another one, upadacitinib, has reported positive phase 3 results but is not approved for alopecia areata at the time of writing.

Effectiveness is only half the picture. These are powerful immune-modulating drugs with serious safety considerations. Their official warnings cover serious infections, mortality, cancer, major cardiovascular events and blood clots. A dermatologist is the right person to decide whether they suit you. Treatment requires monitoring.

The Risk of Koebnerization

Koebnerization means that an injury to the skin can trigger the underlying condition in that spot. Some alopecia areata patients experience this. So the surgical trauma of a transplant may trigger new patches in the treated area or the donor area.

Our Guidance

Do not seek a hair transplant as your first response to alopecia areata. See a dermatologist first. Explore medical options, including JAK inhibitors, before any surgical discussion. If the condition is stable and medical options have been exhausted, then consult a surgeon with documented alopecia areata experience.

This is general information, not medical advice. It is not a substitute for a dermatologist or prescribing clinician. Foxpare is an information and matching service, not a medical provider.

Sources

  • US FDA. Approval of baricitinib (Olumiant) for severe alopecia areata, 2022.
  • US FDA. Approval of ritlecitinib (Litfulo) for severe alopecia areata, 2023.
  • US FDA. Approval of deuruxolitinib (Leqselvi) for severe alopecia areata, 2024.
  • US prescribing information for JAK inhibitors, boxed warnings (serious infections, mortality, malignancy, MACE, thrombosis).
  • Sanchez K. et al. Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review. Dermatology and Therapy, 2025.